November 08, 2024

FDA Approves Novel Combination for Gastric or Gastroesophageal Junction Adenocarcinoma

The U.S. Food and Drug Administration approved zolbetuximab-clzb (Vyloy), a claudin 18.2-directed cytolytic antibody, with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line tr...

The ASCO Post

April 22, 2024

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

May 03, 2023

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–clau...

The ASCO Post

June 13, 2023

Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding

Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequent...

The ASCO Post

January 31, 2023

Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study

Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Fi...

The ASCO Post

December 21, 2023

Expert Point of View: Elizabeth Smyth, MD

Dr. Elizabeth Smyth from Oxford University Hospitals NHS Foundation Trust provides insights on the promising results and challenges of CMG901, a targeted antibody-drug conjugate, for advanced gastric or gastroesophageal junction cancer treatment.

The ASCO Post

February 13, 2023

Expert Point of View: David Wang, MD, PhD

Dr. David Wang discusses the significant survival benefit shown by zolbetuximab in the SPOTLIGHT trial for advanced gastric cancer, shedding light on its potential as a predictive biomarker.

The ASCO Post

March 10, 2023

Expert Point of View: David Wang, MD, PhD

Dr. David Wang discusses the lasting clinical benefit demonstrated in CheckMate 649 and insights from the RATIONALE 305 study.

The ASCO Post